CRBU
Caribou Biosciences, Inc.
There isn't enough reported data to score CRBU yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CRBU Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Unavailable |
CRBU's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRBU PE Valuation
CRBU has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CRBU Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CRBU's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CRBU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.03 | +$0.67 |
| Q2 2026 | -$1.08 | +$0.70 |
| Q1 2026 | -$1.42 | +$0.20 |
| Q4 2025 | -$1.59 | +$0.06 |
| Q3 2025 | -$1.70 | -$0.12 |
| Q2 2025 | -$1.78 | -$0.46 |
| Q1 2025 | -$1.62 | -$0.24 |
| Q4 2024 | -$1.65 | -$0.27 |
CRBU is still losing money, but far less than before: $1.03 per share over the past year, against $2.86 at its worst in late 2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CRBU on earnings quality, reporting a profit while its opponent remains loss making.
CRBU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6M | -27% |
| Q2 2026 | $1.5M | -44% |
| Q1 2026 | $2.4M | +1.9% |
| Q4 2025 | $3.9M | +90% |
| Q3 2025 | $2.2M | +8.6% |
| Q2 2025 | $2.7M | -23% |
| Q1 2025 | $2.4M | -3.1% |
| Q4 2024 | $2.1M | -42% |
CRBU's revenue fell from its 2023 peak and has held roughly level since: $2M last quarter, down 27% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1720% | -383 points |
| Q2 2026 | -1690% | +94 points |
| Q1 2026 | -1096% | +727 points |
| Q4 2025 | -722% | +1150 points |
| Q3 2025 | -1338% | +552 points |
| Q2 2025 | -1784% | -528 points |
| Q1 2025 | -1824% | +70 points |
| Q4 2024 | -1872% | -819 points |
CRBU's operating margin was −1720% last quarter, down 383 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CRBU on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CRBU on profitability, with a higher operating margin.
CRBU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$22.5M | +$2.8M |
| Q2 2026 | -$22.8M | +$5.9M |
| Q1 2026 | -$27.1M | +$10.7M |
| Q4 2025 | -$20.6M | +$15.4M |
| Q3 2025 | -$25.3M | +$8M |
| Q2 2025 | -$28.7M | +$6.4M |
| Q1 2025 | -$37.8M | +$884K |
| Q4 2024 | -$36M | -$12.3M |
CRBU has burned cash in almost every quarter: −$93M over the past year, against −$128M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CRBU on cash generation, producing positive trailing cash flow while its opponent burns cash.
CRBU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.5% | +6.6M shares |
| 1 year | +15% | +14.2M shares |
| 3 years | +28% | +23.8M shares |
| 5 years | +134% | +61.6M shares |
| Available history | +289% | +79.9M shares |
CRBU has 108M diluted shares, up 15% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CRBU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CRBU Net Leverage
CRBU's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CRBU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.9 | Oversold |
| Stochastic | 1.8 | Oversold |
CRBU's weekly RSI is 26 (oversold) and its Stochastic is 2 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CRBU PE vs Healthcare Sector
CRBU has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CRBU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.65 | 42% below |
| 20 week MA | $1.21 | 69% below |
| 50 week MA | $1.57 | 76% below |
| 100 week MA | $1.56 | 76% below |
| 200 week MA | $2.98 | 87% below |
CRBU is in a downtrend: it's below all five of its weekly moving averages, and 87% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CRBU on trend strength, trading above more of its moving averages.
CRBU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $16.3 | $16.2 | -0.9% |
| 2022 | $16.2 | $6.16 | -62% |
| 2023 | $6.16 | $5.73 | -7% |
| 2024 | $5.73 | $1.67 | -71% |
| 2025 | $1.67 | $1.70 | +1.8% |
| 2026 YTD | $1.70 | $0.38 | -78% |
CRBU has finished lower in four of the last five years. It's down 78% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CRBU on returns for 2026, with the stronger performance.